Jump to content

Muscarinic acetylcholine receptor M1

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 134.173.78.1 (talk) at 07:46, 8 October 2014 (Effects). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Template:PBB The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor.

This receptor is found mediating slow EPSP at the ganglion in the postganglionic nerve[citation needed], is common in exocrine glands and in the CNS.[1][2]

It is predominantly found bound to G proteins of class Gq[3][4] that use upregulation of phospholipase C and, therefore, inositol trisphosphate and intracellular calcium as a signalling pathway. A receptor so bound would not be susceptible to CTX or PTX. However, Gi (causing a downstream decrease in cAMP) and Gs (causing an increase in cAMP) have also been shown to be involved in interactions in certain tissues, and so would be susceptible to PTX and CTX respectively.

Effects

Mechanism

It couples to Gq, and, to a small extent, Gi and Gs. This results in slow EPSP and decreased K+ conductance[6][7] It is preassembled to the Gq heterotrimer through a polybasic c-terminal domain.[3]

Ligands

Agonists

Allosteric modulators

  • benzylquinolone carboxylic acid[8]
  • VU-0090157[9]
  • VU-0029767[9]

Antagonists

Gene

The receptor is encoded by human gene CHRM1.[5] It is localized to 11q13.[5]

See also

References

  1. ^ Johnson, Gordon (2002). PDQ Pharmacology (2nd ed.). Hamilton, Ontario: BC Decker Inc. pp. 311 pages. ISBN 1-55009-109-3.
  2. ^ Richelson, Elliott (2000). "Cholinergic Transduction, Psychopharmacology - The Fourth Generation of Progress". American College of Neuropsychopharmacology. Retrieved 27 October 2007.
  3. ^ a b Kou Qin, Chunmin Dong, Guangyu Wu & Nevin A Lambert (August 2011). "Inactive-state preassembly of Gq-coupled receptors and Gq heterotrimers". Nature Chemical Biology. 7 (11): 740–747. doi:10.1038/nchembio.642. PMID 21873996.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Burford NT, Nahorski SR (1996). "Muscarinic m1 receptor-stimulated adenylate cyclase activity in Chinese hamster ovary cells is mediated by Gs alpha and is not a consequence of phosphoinositidase C activation". Biochem. J. 315 (Pt 3): 883–8. PMC 1217289. PMID 8645172.
  5. ^ a b c d "Entrez Gene: CHRM1 cholinergic receptor, muscarinic 1".
  6. ^ a b c d e f g h i j Rang HP, Dale MM, Ritter JM, Moore PK (2003). "10". Pharmacology (5th ed.). Elsevier Churchill Livingstone. p. 139. ISBN 0-443-07145-4.{{cite book}}: CS1 maint: multiple names: authors list (link)
  7. ^ Uchimura N, North RA (1 March 1990). "Muscarine reduces inwardly rectifying potassium conductance in rat nucleus accumbens neurones". J. Physiol. (Lond.). 422 (1): 369–80. PMC 1190137. PMID 1693682.
  8. ^ Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, Christian EP, Doherty JJ, Quirk MC, Snyder DH, Lah JJ, Levey AI, Nicolle MM, Lindsley CW, Conn PJ (November 2009). "A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning". J. Neurosci. 29 (45): 14271–86. doi:10.1523/JNEUROSCI.3930-09.2009. PMC 2811323. PMID 19906975.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ a b Marlo JE, Niswender CM, Days EL; et al. (2008). "Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity". Mol. Pharmacol. 75 (3): 577–88. doi:10.1124/mol.108.052886. PMC 2684909. PMID 19047481. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  10. ^ Edwards Pharmaceuticals, Inc.; Belcher Pharmaceuticals, Inc. (May 2010), DailyMed, U.S. National Library of Medicine, retrieved 13 January 2013{{citation}}: CS1 maint: date and year (link)

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.